Krka enjoyed its “strongest half-year sales to date,” albeit with sales of prescription pharmaceuticals at €689.1m ($813m) remaining “at a similar level as last year,” according to preliminary unaudited results for the first six months of 2021 just released by the Slovenian firm.
Prescription pharmaceuticals amounted to a little over 85% of group turnover, which grew by 1% to €806.5m, driven by stronger...






